AstraZeneca to withdraw marketing authorisations for Covid-19 vaccine

ASTRAZENECA: AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its Covid-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.

Read more: AstraZeneca admits potential for blood clots from Covid vaccine in rare instances

AstraZeneca attributed the decision to decline in demand for Vaxzervria, which is no longer being manufactured or supplied.

The company also said it would proceed to withdraw the vaccine Vaxzevria’s marketing authorisations within Europe.

“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

The firm’s application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.

London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as Covid-19 medicine sales declined.